Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 23:16:1618110.
doi: 10.3389/fimmu.2025.1618110. eCollection 2025.

BRICS sequential therapeutic regimen as first-Line treatment for PD-L1-negative metastatic non-small cell lung cancer patients harboring EGFR/ALK wild-type status: a retrospective study

Jianxin Chen #  1 , Jian Wang #  2   1 , Weiqiang Fang  3 , Yating Wu  3 , Hang Li  3 , Hui Xu  3 , Yunyun Zhu  3 , Yanran Cheng  3 , Zongyang Yu  3 , Yonghai Peng  3
Affiliations

BRICS sequential therapeutic regimen as first-Line treatment for PD-L1-negative metastatic non-small cell lung cancer patients harboring EGFR/ALK wild-type status: a retrospective study

Jianxin Chen et al. Front Immunol. .

Abstract

Background: Patients with PD-L1-negative, EGFR/ALK wild-type metastatic non-small cell lung cancer (NSCLC) exhibit limited responses to immune checkpoint inhibitors (ICIs). This study evaluates the BRICS regimen-a sequential approach combining stereotactic body radiotherapy (SBRT), probiotics, PD-1 inhibitors, and low-dose chemotherapy-to overcome immunotherapy resistance.

Methods: This retrospective study included 23 patients treated between 2018 to 2024. Eligibility criteria: confirmed PD-L1-negative NSCLC, no actionable mutations, and measurable lesions. The BRICS regimen comprised SBRT (24 Gy in 3 fractions) to a single lesion, oral probiotics (6 g/day), low-dose chemotherapy, and PD-1 inhibitors administered every 21 days for six cycles. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.

Results: Median age was 62 years; 82.6% were male. ORR and DCR were both 95.7%. Median PFS was 16 months (95% CI: 9.11-22.89), and median OS was 32.7 months (95% CI: 11.53-53.87). In subgroup analysis based on prior treatment status, median PFS and OS were numerically longer in treatment-naïve patients compared to previously treated patients (mPFS: 20.0 vs. 13.6 months; mOS: 48.0 vs. 18.0 months), though without statistical significance (P > 0.05). Poor ECOG performance status predicted poorer PFS (HR=9.908, p=0.013) and OS (HR=26.406, p=0.008). Adverse events were predominantly grade 1 to 2 (fatigue:13.2%, rash:8.7%), with no grade ≥3 toxicities.

Conclusions: The BRICS regimen demonstrated promising efficacy and safety in PD-L1-negative NSCLC, potentially overcoming resistance through multimodal immunomodulation. clinical benefit was observed regardless of treatment line, with a trend toward improved outcomes when administered as first-line therapy. Prospective trials are warranted to validate these findings and explore mechanisms underlying radiotherapy-microbiome-chemotherapy synergy.

Keywords: BRICS regimen; NSCLC; efficacy; first-line treatment; retrospective study.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Treatment protocol of BRICS sequential therapeutic regimen.
Figure 2
Figure 2
Kaplan-Meier survival curves of PFS in 23 patients.
Figure 3
Figure 3
Kaplan-Meier survival curves of OS in 23 patients.
Figure 4
Figure 4
Kaplan–Meier survival curves of PFS stratified by treatment history.
Figure 5
Figure 5
Kaplan–Meier survival curves of OS stratified by treatment history.
Figure 6
Figure 6
Univariate analysis of prognostic factors for PFS.
Figure 7
Figure 7
Univariate analysis of prognostic factors for OS.
See this image and copyright information in PMC

References

    1. Wang J, Liu B, Zheng Q, Xiao R, Chen J. Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report. Front Oncol. (2024) 14:1507658. doi: 10.3389/fonc.2024.1507658 - DOI - PMC - PubMed
    1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: Cancer J Clin. (2025) 75:10–45. doi: 10.3322/caac.21871 - DOI - PMC - PubMed
    1. Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. (2023) 23:162. doi: 10.1186/s12935-023-02990-y - DOI - PMC - PubMed
    1. Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. (2021) 22. doi: 10.3390/ijms22168661 - DOI - PMC - PubMed
    1. Feldt SL, Bestvina CM. The role of MET in resistance to EGFR inhibition in NSCLC: A review of mechanisms and treatment implications. Cancers. (2023) 15. doi: 10.3390/cancers15112998 - DOI - PMC - PubMed

MeSH terms